Determination of ifosfamide by HPLC using on-line sample preparation

Journal of Chemotherapy

Volumn 11, Issue 1, 1999, Pages 69-73

  Zolezzi, Carola ^a   Ferrari, S ^a   Bacci, G ^a   Fasano, M C ^a   Sormani, G ^a   Pizzoferrato, A ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

HPLC determination; Ifosfamide; Sarcoma chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; IFOSFAMIDE; OXAZAPHOSPHORINE DERIVATIVE; TROFOSFAMIDE;

ACCURACY; ANALYTIC METHOD; ARTICLE; AUTOANALYSIS; CALIBRATION; DEVICE; DRUG DETERMINATION; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTERMETHOD COMPARISON; REPRODUCIBILITY; SOLID PHASE EXTRACTION; STANDARD;

EID: 0032973246     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1999.11.1.69     Document Type: Article

References (17)

1. 1 Brade WP, Herdrich K, Varini M. Ifosfamide pharmacology, safety and therapeutic potential. Cancer Treat Rev 1985; 12: 1-47.
2. 2 Granvil CP, Ducharme J, Leyland-Jones B, Trudeau MW, Wainer I. Stereoselective pharmacokinetics of ifosfamide and its 2-and 3-N-dechloroethylated metabolites in female cancer patients. Cancer Chemother Pharmacol 1996; 37: 451-456.
3. 3 Kaijser GP, Keizer HJ, Beijnen JH, Bult A, Underberg WJM. Pharmacokinetics of ifosfamide, 2-and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide. Anticancer Res 1996; 16: 3247-3258.
4. 4 Chang TKH, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosfamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993; 53: 5629-5637.
5. 5 Walker D, Flinois J-P, Monkman SC, et al. Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem Pharmacol 1994; 47: 1157-1161.
6. 6 Kurowski V, Cerny T, Kupfer A, Wagner T. Metabolism and pharmacokinetics of oral and intravenous ifosfamide. J Cancer Clin Oncol 1991; 117 (Suppl IV): 148-153.
7. 7 Leblanc GA, Waxman DJ. Mechanism of cyclophosphamide action on hepatic P-450 expression. Cancer Res 1990; 50: 5720-5726.
8. 8 Sladek N. Metabolism of oxazaphosphorine. Pharmacol Ther 1988; 37: 301-355.
9. 9 Connors TA, Cox PJ, Farmer PB, Foster AB, Jarman M. Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide. Biochem Pharmacol 1973; 23: 115-129.
10. 10 Boddy AV, Yule SM, Wyllie R, Price L, Pearson ADJ, Idle JR. Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration. Cancer Chemother Pharmacol 1996; 38: 147-154.
11. 11 Lind MJ, Roberts HL, Thatcher N, Idle JR. The effect of route of administration and fractionation of dose on the metabolism of ifosfamide. Cancer Chemother Pharmacol 1990; 26: 105-111.
12. 12 Wainer IW, Ducharme J, Granvil CP, Trudeau M, Leyland-Jones B. Ifosfamide Stereoselective dechloroethylation and neurotoxicity. Lancet 1994; 383: 982-983.
13. 13 Lewis LD, Fitzgerald DL, Mohan P, Thatcher N, Harper PG, Rogers HJ. The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients. Br J Clin Pharmacol 1991; 31: 77-82.
14. 14 Kaijser GP, Korst JH, Beijnen JH, Underberg WJM. The analysis of ifosfamide and its metabolites. Anticancer Res 1993; 13: 1311-1324.
15. 15 Burton LC, James CA. Rapid method for the determination of ifosfamide and cyclophosphamide in plasma by high-performance liquid chromatography with solid-phase extraction. J Chromatogr 1988; 431: 450-454.
16. 16 Margison JM, Wilkinson PM, Cerny T, Thatcher N. A simple quantitative HPLC assay for ifosfamide in biological fluids. Biomed Chromatogr 1986; 1: 101-103.
17. 17 Masurel D, Wainer IW. Analytical and preparative high performance liquid chromatographic separation of the enantiomers of ifosfamide, cyclofosfamide and trofosfamide and their determination in plasma. J Chromatogr 1989; 490: 133-143.